The investments highlight a shift toward moving sophisticated diagnostics upstream. ImageAiD utilizes Mayo Clinic-validated research paired with a handheld Doppler device to identify PAD years before physical symptoms emerge. Moonrise Medical focuses on operational efficiency, automating ultrasound assessments and Pedal Acceleration Time calculations to allow front-line clinicians to evaluate vascular health without needing specialized sonographers.
Jetstream Venture Fund Targets Vascular Diagnostics with New AI Bets
Peripheral Artery Disease affects 12 million Americans, yet diagnostic tools often arrive only after tissue damage takes hold. Seeking to bridge this gap, Scottsdale-based Jetstream Venture Fund has added ImageAiD and Moonrise Medical to its portfolio, prioritizing early-stage AI platforms capable of bringing complex vascular assessments into primary care settings.
Mike Shufeldt, portfolio manager at Jetstream, emphasized that current clinical practices remain too reactive. By leveraging a leadership team with deep roots in clinical medicine and commercialization, the fund aims to capture specialized medical startups that often evade broader venture networks. The fund maintains a $5,000 minimum investment threshold, positioning these healthtech tools alongside its existing holdings in companies like SpaceX and Shield AI.
Comments (0)
No comments yet. Be the first!